| Literature DB >> 32326636 |
Mirco Vacca1, Giuseppe Celano1, Francesco Maria Calabrese1, Piero Portincasa2, Marco Gobbetti3, Maria De Angelis1.
Abstract
The complex polymicrobial composition of human gut microbiota plays a key role in health and disease. Lachnospiraceae belong to the core of gut microbiota, colonizing the intestinal lumen from birth and increasing, in terms of species richness and their relative abundances during the host's life. Although, members of Lachnospiraceae are among the main producers of short-chain fatty acids, different taxa of Lachnospiraceae are also associated with different intra- and extraintestinal diseases. Their impact on the host physiology is often inconsistent across different studies. Here, we discuss changes in Lachnospiraceae abundances according to health and disease. With the aim of harnessing Lachnospiraceae to promote human health, we also analyze how nutrients from the host diet can influence their growth and how their metabolites can, in turn, influence host physiology.Entities:
Keywords: Lachnospiraceae; disease; gut microbial metabolites; gut microbial pathways; gut microbiota; health
Year: 2020 PMID: 32326636 PMCID: PMC7232163 DOI: 10.3390/microorganisms8040573
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Phylogeny of taxa belonging to the Lachnospiraceae family. Sequences have been retrieved from the RefSeq Targeted Loci Project included in the National Center for Biotechnology Information (NCBI) database using the following combined search: txid186803[ORGN] AND (33175[Bioproject] OR 33317[Bioproject] of bacterial 16S ribosomal RNA. The nucleotide sequences have been multiply aligned using MAFFT tool version 7.427 (https://mafft.cbrc.jp/alignment/software/) and the approximately-maximum-likelihood phylogenetic tree has been inferred from the nucleotide alignments by using the general time-reversible model (GTR).
Figure 2Reconstruction of the main microbial pathways associated to Lachnospiraceae in human gut. The panel in blue shows a schematic representation of the metabolic pathways involved in the biosynthesis of acetate and butyrate, as well as the main pathways of carbohydrate degradation (yellow). The green panel shows a schematic representation of metabolic pathways of aromatic amino acids involved in the biosynthesis of indole-propionic acid, indole, phenol, and p-cresol.
Summary of the main metabolic pathways and corresponding Lachnospiraceae taxa involved in the production of compounds affecting human health. The beneficial and harmful effects are referred to the main diseases showing Lachnospiraceae variations.
| Taxa | Pathways (EC) | Metabolites | Beneficial Effect * | Harmful Effect | ||
|---|---|---|---|---|---|---|
| Butyril-CoA:acetate CoA trasferase (2.8.3.8) | butyrate | MD LD IBD | Strengthen the intestinal barrier through up-regulation of tight junctions and mucin production by enterocytes [ | MD LD | ||
| Anti-inflammatory effects by induction of regulatory T cells, downregulation of pro-inflammatory cytokines and the Toll-like receptor (TLR) 4 receptors [ | ||||||
| Activation of G protein-coupled receptor (GPR) 43 involved in the modulation of inflammation and stimulation of glucagon-like peptides (GLP) 1 and gastric inhibitory polypeptide; modulate appetite, reinforce insulin sensitivity and glucose metabolism [ | ||||||
|
| ||||||
| Activation of fatty acid oxidation and de novo synthesis and lipolysis inhibition, which in turn, decrease circulating lipid plasma levels and body weight [ | ||||||
| GPR 43 binding suppresses colon inflammation therefore protect liver and down- regulate insulin signal transduction in adipose tissue [ | Elevated energy extraction in form of SCFAs related to a high intake of dietary carbohydrates [ | |||||
| MD LD | Lower expression of peroxisome proliferator-activated receptor-γ, and stimulation of uncoupling protein 2 and stimulate oxidative metabolism in liver and adipose tissue [ | Intestinotrophic effects of SCFAs mediated by GLP-2 which contributes to the development or maintenance of obesity through elevated intestinal absorption of energy (kcal) intake [ | ||||
| MD | Inhibition of Histone Deacetylases by altering the acetylation pattern of H3 and H4 histones and inducing beta-cell proliferation by inhibiting the p38/ERK apoptotic pathway [ | Dyslipidemia due to elevation of cholesterol and triglycerides that increasing the levels of Acetyl-CoA in obese patient and metabolic disturbance [ | ||||
| Butyrate kinase | MDDMSS | |||||
|
| (2.7.2.7) | IBD | Significantly reduced circulating LPS levels [ | |||
| CKD | ||||||
| MSS | Increase anti-inflammatory CD4+ regulatory T cells and decrease pro-inflammatory Th1 and Th17 cells of in central nervous system. [ | |||||
| Propanediol pathways (4.2.1.28, 1.2.1.87, 2.8.3.1.) | propionate | MD LD CKD | SCFA-stimulated GPR41 induce leptin production by adipocytes and lipid profile regulation [ | MD | Substantial amounts of propionate entering into the mitochondrial tricarboxylic acid (TCA) cycle bypass the first four TCA enzymes, causing a shift in the cycle with a potential toxic effect [ | |
|
| ||||||
| Acrylate pathway (4.2.1.4, 1.3.8.7, 2.8.3.1.) | ||||||
| Mucin degradation (glycoside hydrolases (GH)) | IBD | Disproportionate increase of mucolytic bacteria could explain increased total mucosa-associated bacteria in IBD [ | ||||
|
| ||||||
| acetate | MD LD CKD IBD | Inhibition of entero-pathogens; reduction of luminal pH, and increases the absorption of dietary nutrient [ | MD | Increased production leads to activation of the parasympathetic nervous system and stimulation of insulin secretion. The role of acetate in driving obesity depends on the gut microbiota and on dietary fiber intake [ | ||
| Acetate kinase | ||||||
| (2.7.2.1) | LD | De novo lipogenesis and cholesterol genesis in the liver [ | ||||
| Marked reduction in lipid accumulation in the adipose tissue, protects against accumulation of fat in the liver, improving the glucose tolerance [ | ||||||
|
| ||||||
| CKD | The derived serum p-Cresyl sulphate a protein-derived uremic toxin is linked to cardiovascular and kidney damage [ | |||||
| Tyrosine | ||||||
| (2.6.1.1, 2.6.1.9, 4.1.1.83) | ||||||
| Tyrosine (4.1.99.2) | phenol | |||||
| Tryptophan (4.1.99.1) | indole | MD LD CKD IBD | Activation of aryl-hydrocarbon receptor by microbially derived indoles, these molecules promotes tissue repair and homeostasis involving interleukin (IL)-22 [ | CKD | Indole and indoxyl sulfate affect arterial blood pressure via peripheral and central mechanisms dependent on serotonin signaling and contribute do cardiovascular disease in renal insufficiency [ | |
|
| ||||||
|
| Tryptophan | indole-propionic acid | MD | Engage the pregnane X receptor, leading to the upregulation of genes that regulate intestinal permeability and to the downregulation of TNF-α expression by enterocytes [ | ||
| MSS | Potent radical scavenging activity and neuroprotective properties [ | |||||
* The beneficial/harmful effects are referred to the relative diseases showed on the left side; Abbreviations: MD, metabolic diseases; LD, liver disease; IBD, inflammatory bowel disease; MDD, major depressive disorder; MSS, multiple sclerosis syndrome; CKD, chronic kidney disease; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; TNF-α, tumor necrosis factor.
Taxa of Lachnospiraceae detected in different diseases in humans and animal models. Number of samples and changes in taxon are also indicated.
| Taxon | Change | Principal Disease | Patient Type/Model ( | Ref. |
|---|---|---|---|---|
| ↑ | MD | Women with obesity + metabolic syndrome ( | [ | |
| Lachnospiraceae | ↑ | MD | Individuals with glucose metabolism disorder ( | [ |
| Lachnospiraceae | ↑ | MD | Male patients ( | [ |
| Lachnospiraceae | ↑ | MD | Male C57BL/6 mice ( | [ |
|
| ↑ | Prediabetic stage | Infants with serum autoantibody positivity ( | [ |
|
| ↑ | Diabetes T1 | Infants with T1D ( | [ |
| Lachnospiraceae | ↑ | Diabetes T2 | Patients with T2D ( | [ |
| Lachnospiraceae | ↑ | Diabetes T2 | Cg-Dock7m +/+Leprdb/J [ | [ |
| ↑ | NAFLD | Male patients ( | [ | |
|
| ↑ | NASH | Male patients ( | [ |
| Lachnospiraceae | ↑ | PSC–IBD | Patients ( | [ |
|
| ↑ | PSC | Patients ( | [ |
| Lachnospiraceae | ↑ | IgAN | Patients IgAN progressor ( | [ |
| Lachnospiraceae | ↑ | CKD | Male Sprague–Dawley rats ( | [ |
| ↑ | Renal dysfunction | Individuals with eGFR < 60mL/min/1.73m2 ( | [ | |
|
| ↑ | CKD | Nephrectomy rats ( | [ |
| Clostridiales ( | ↓ | CD | Children and adolescents (<17 years) with newly diagnosed CD ( | [ |
| L- | ↓ | ICD | Patients with ICD ( | [ |
| L- | ↓ | CCD | Patients with CCD and with normal ileum ( | [ |
| Lachnospiraceae | ↓ | CD | Tissue samples from CD patients ( | [ |
| Lachnospiraceae | ↓ | UC | Tissue samples from UC patients ( | [ |
| Lachnospiraceae | ↑ | AIEC infections | TLR5-deficient mice ( | [ |
| Lachnospiraceae | ↑ | CD | Bacterial isolation from mouse cecum ( | [ |
| ↑ | MDD | MDD subjects ( | [ | |
| ↑ | MDD | Active-MDD patients ( | [ | |
| ↑ | MSS | Patients ( | [ |
Abbreviations:↑, increase; ↓, decrease; MD, metabolic diseases; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease; IgAN, immunoglobulin A nephropathy; CKD, chronic kidney disease; AIEC, adherent-invasive Escherichia coli; CD, Crohn’s disease; ICD, ileal Crohn’s disease; CCD, Crohn’s disease restricted to the colon; UC, ulcerative colitis; MDD, major depressive disorder; MSS, multiple sclerosis. syndrome.